97 related articles for article (PubMed ID: 20423465)
1. Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients.
Zhang GZ; Jiao SC; Meng ZT
J Exp Clin Cancer Res; 2010 Apr; 29(1):38. PubMed ID: 20423465
[TBL] [Abstract][Full Text] [Related]
2. SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
Greystoke A; Steele N; Arkenau HT; Blackhall F; Md Haris N; Lindsay CR; Califano R; Voskoboynik M; Summers Y; So K; Ghiorghiu D; Dymond AW; Hossack S; Plummer R; Dean E
Br J Cancer; 2017 Sep; 117(7):938-946. PubMed ID: 28950288
[TBL] [Abstract][Full Text] [Related]
3. A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer.
Mubarak N; Gaafar R; Shehata S; Hashem T; Abigeres D; Azim HA; El-Husseiny G; Al-Husaini H; Liu Z
BMC Cancer; 2012 Sep; 12():423. PubMed ID: 23006447
[TBL] [Abstract][Full Text] [Related]
4. Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.
Paz-Ares LG; Altug S; Vaury AT; Jaime JC; Russo F; Visseren-Grul C
BMC Cancer; 2010 Mar; 10():85. PubMed ID: 20211022
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
Davies JM; Dhruva NS; Walko CM; Socinski MA; Bernard S; Hayes DN; Kim WY; Ivanova A; Keller K; Hilbun LR; Chiu M; Dees EC; Stinchcombe TE
Lung Cancer; 2011 Feb; 71(2):151-5. PubMed ID: 20580118
[TBL] [Abstract][Full Text] [Related]
6. KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer.
Yamamoto N; Satouchi M; Doi T; Fujiwara Y; Yanagitani N; Kawa Y; Yoh K; Leopold L; Munteanu M; Sawada T; Han S; Noguchi K; Nishio M
Invest New Drugs; 2024 Jun; 42(3):261-271. PubMed ID: 38530565
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study.
Minami S; Kijima T; Takahashi R; Kida H; Nakatani T; Hamaguchi M; Takeuchi Y; Nagatomo I; Yamamoto S; Tachibana I; Komuta K; Kawase I
BMC Cancer; 2012 Jul; 12():296. PubMed ID: 22809298
[TBL] [Abstract][Full Text] [Related]
8. Successful switch to cisplatin-based chemotherapy in a patient with lung cancer who developed a carboplatin-induced hypersensitivity reaction.
Nagata Y; Toyokawa G; Sugiyama A; Shimamatsu S; Saitoh O; Okubo H; Ueda H
J Oncol Pharm Pract; 2024 Jun; 30(4):772-776. PubMed ID: 38404012
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.
Ceresoli GL; Castagneto B; Zucali PA; Favaretto A; Mencoboni M; Grossi F; Cortinovis D; Del Conte G; Ceribelli A; Bearz A; Salamina S; De Vincenzo F; Cappuzzo F; Marangolo M; Torri V; Santoro A
Br J Cancer; 2008 Jul; 99(1):51-6. PubMed ID: 18542071
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of calculating carboplatin dosage in carboplatin-pemetrexed therapy as the first-line therapy for Chinese patients with advanced lung adenocarcinoma.
Zhu Y; Xing P; Wang S; Ma D; Mu Y; Li X; Xu Z; Li J
Thorac Cancer; 2018 Mar; 9(3):400-407. PubMed ID: 29377581
[TBL] [Abstract][Full Text] [Related]
11. Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer.
Kutluk Cenik B; Sun H; Gerber DE
Lung Cancer; 2013 Jun; 80(3):326-32. PubMed ID: 23499397
[TBL] [Abstract][Full Text] [Related]
12. Ganetespib in Combination with Pemetrexed-Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial.
Fennell DA; Danson S; Woll PJ; Forster M; Talbot D; Child J; Farrelly L; Sharkey A; Busacca S; Ngai Y; Hackshaw A; Wheeler GM
Clin Cancer Res; 2020 Sep; 26(18):4748-4755. PubMed ID: 32669375
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab-induced laryngeal necrosis.
Hartl DM; Bahleda R; Hollebecque A; Bosq J; Massard C; Soria JC
Ann Oncol; 2012 Jan; 23(1):276-278. PubMed ID: 22056850
[No Abstract] [Full Text] [Related]
14. Platinum drugs in the treatment of non-small-cell lung cancer.
Cosaert J; Quoix E
Br J Cancer; 2002 Oct; 87(8):825-33. PubMed ID: 12373594
[TBL] [Abstract][Full Text] [Related]
15. Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report.
Zhao W; Zhu M; Wang R; Tong Z
Anticancer Drugs; 2023 Jun; 34(5):686-689. PubMed ID: 36206106
[TBL] [Abstract][Full Text] [Related]
16. Use of Novel National Data Sets to Monitor Chemotherapy Use and Outcomes: A Retrospective Cohort Study of Non-Small-Cell Lung Cancer in Aotearoa New Zealand.
Minhinnick AM; Dunn AH; Arabnejad V; Paddison JS; Jackson CGCA; Pointer SM; Gurney JK; Cameron LB
JCO Oncol Pract; 2024 Mar; 20(3):401-408. PubMed ID: 38206292
[TBL] [Abstract][Full Text] [Related]
17. Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma.
Kesari S; Wagle N; Carrillo JA; Sharma A; Nguyen M; Truong J; Gill JM; Nersesian R; Nomura N; Rahbarlayegh E; Barkhoudarian G; Sivakumar W; Kelly DF; Krauss H; Bustos MA; Hoon DSB; Anker L; Singh AS; Sankhala KK; Juarez TM
Clin Cancer Res; 2024 Jan; 30(2):323-333. PubMed ID: 38047868
[TBL] [Abstract][Full Text] [Related]
18. Response- and Progression-Based End Points in Trial and Observational Cohorts of Patients With NSCLC.
Lu Y; Langerman SS; McCain E; Magee K; Maund SL; Srivastava MK; Samant M
JAMA Netw Open; 2024 May; 7(5):e249286. PubMed ID: 38700864
[TBL] [Abstract][Full Text] [Related]
19. Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non-Small Cell Lung Cancer: The Piedmont Study.
Eisner JR; Mayhew GM; Davison JM; Beebe KD; Shibata Y; Guo Y; Farhangfar C; Farhangfar F; Uronis JM; Conroy JM; Milburn MV; Hayes DN; Mileham KF
Clin Cancer Res; 2023 Aug; 29(16):3203-3213. PubMed ID: 37233991
[TBL] [Abstract][Full Text] [Related]
20. A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer.
Wang SS; Zimmermann M; Zhang H; Lin TY; Malfatti M; Haack K; Turteltaub KW; Cimino GD; de Vere White R; Pan CX; Henderson PT
Int J Cancer; 2017 Aug; 141(3):604-613. PubMed ID: 28437852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
